Abstract

Background. There is a need to identify the complex interplay between various physiological mechanisms in primary ciliary dyskinesia (PCD) and cystic fibrosis (CF). The study investigated the interaction between respiratory function, exercise capacity, muscle strength, and inflammatory and oxidant/antioxidant responses in patients with PCD and CF.

Methods. The study included 30 PCD patients, 30 CF patients, and 29 age and sex-matched healthy subjects. Exercise capacity was assessed using the modified shuttle walk test (MSWT). Handgrip strength (HGS) was used to evaluate general muscle strength. Oxidative stress-inflammatory parameters were also assessed. Pulmonary function test was performed by spirometry. Regarding the forced expiratory volume in 1 second (FEV1) z-score, patients with PCD and CF were subdivided into normal, mild, and severe/moderate groups.

Results. Forced vital capacity (FVC) z-scores were lower in PCD and CF patients than controls. FEV1, FEV1/FVC, peak expiratory flow (PEF), and forced mid expiratory flow (FEF25-75%) z-scores were lower in PCD than in the other groups. HGS was lower in both mild PCD and normal CF patients relative to the controls. MSWT distance was lower in severe/moderate PCD patients than controls. Catalase (CAT), glutathione S-transferase (GST), glutathione peroxidase (GPx), and malondialdehyde (MDA) levels did not differ significantly among the study groups, but superoxide dismutase (SOD) level in severe/moderate PCD, and glutathione (GSH) level in normal CF were higher than in controls. Interleukin-6 (IL-6) level was higher in patients with normal PCD and CF compared to the controls. IL-1β level was higher in PCD compared to controls. Additionally, correlations among these parameters were also determined in some patient groups.

Conclusion. Homeostasis related to respiratory function, aerobic performance, muscle strength, inflammatory response, and oxidant/antioxidant balance were affected in PCD and CF. Evaluating these mechanisms together may contribute to elucidating the pathophysiology of these rare diseases.

Keywords: aerobic performance, handgrip strength, primary ciliary dyskinesia, cystic fibrosis, oxidative stress-inflammatory parameters

Copyright and license

Copyright © 2024 The Author(s). This is an open access article distributed under the Creative Commons Attribution License (CC BY), which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is properly cited.

How to cite

1.
Kartal Y, Bozdemir Özel C, Çakmak A, et al. The relationship between lung function, exercise capacity, oxidant and antioxidant response in primary ciliary dyskinesia and cystic fibrosis. Turk J Pediatr 2024; 66: 309-322. https://doi.org/10.24953/turkjpediatr.2024.4581

References

  1. Pifferi M, Bush A, Di Cicco M, et al. Health-related quality of life and unmet needs in patients with primary ciliary dyskinesia. Eur Respir J 2010; 35: 787-794. https://doi.org/10.1183/09031936.00051509
  2. Schofield LM, Horobin HE. Growing up with primary ciliary dyskinesia in Bradford, UK: exploring patients experiences as a physiotherapist. Physiother Theory Pract 2014; 30: 157-164. https://doi.org/10.3109/09593985.2013.845863
  3. Lucas JS, Walker WT, Kuehni CE, et al. Primary ciliary dyskinesia. In: Courdier JF, editor. Orphan Lung Diseases Lausanne: ERS Monograph; 2011: 201-217. https://doi.org/10.1183/1025448x.10008310
  4. Ademhan Tural D, Yalçın E, Emiralioglu N, et al. Comparison of inhaled mannitol/dornase alfa combination and daily dornase alfa alone in children with cystic fibrosis. Pediatr Pulmonol 2022; 57: 142-151. https://doi.org/10.1002/ppul.25740
  5. Sommer LM, Alanin MC, Marvig RL, et al. Bacterial evolution in PCD and CF patients follows the same mutational steps. Sci Rep 2016; 6: 28732. https://doi.org/10.1038/srep28732
  6. Hommerding PX, Baptista RR, Makarewicz GT, et al. Effects of an educational intervention of physical activity for children and adolescents with cystic fibrosis: a randomized controlled trial. Respir Care 2015; 60: 81-87. https://doi.org/10.4187/respcare.02578
  7. Madsen A, Green K, Buchvald F, Hanel B, Nielsen KG. Aerobic fitness in children and young adults with primary ciliary dyskinesia. PLoS One 2013; 8: e71409. https://doi.org/10.1371/journal.pone.0071409
  8. Ring AM, Buchvald FF, Holgersen MG, Green K, Nielsen KG. Fitness and lung function in children with primary ciliary dyskinesia and cystic fibrosis. Respir Med 2018; 139: 79-85. https://doi.org/10.1016/j.rmed.2018.05.001
  9. Lorenzon Dos Santos J, Quadros AS, Weschenfelder C, Garofallo SB, Marcadenti A. Oxidative stress biomarkers, nut-related antioxidants, and cardiovascular disease. Nutrients 2020; 12: 682. https://doi.org/10.3390/nu12030682
  10. Niki E. Oxidant-specific biomarkers of oxidative stress. Association with atherosclerosis and implication for antioxidant effects. Free Radic Biol Med 2018; 120: 425-440. https://doi.org/10.1016/j.freeradbiomed.2018.04.001
  11. Zinellu E, Zinellu A, Fois AG, et al. Oxidative stress biomarkers in chronic obstructive pulmonary disease exacerbations: a systematic review. Antioxidants (Basel) 2021; 10: 710. https://doi.org/10.3390/antiox10050710
  12. Cockx M, Gouwy M, Van Damme J, Struyf S. Chemoattractants and cytokines in primary ciliary dyskinesia and cystic fibrosis: key players in chronic respiratory diseases. Cell Mol Immunol 2018; 15: 312-323. https://doi.org/10.1038/cmi.2017.118
  13. Magallón M, Pastor S, Carrión AE, et al. Oxidative stress and endoplasmic reticulum stress in rare respiratory diseases. J Clin Med 2021; 10: 1268. https://doi.org/10.3390/jcm10061268
  14. Tucker MA, Berry B, Seigler N, et al. Blood flow regulation and oxidative stress during submaximal cycling exercise in patients with cystic fibrosis. J Cyst Fibros 2018; 17: 256-263. https://doi.org/10.1016/j.jcf.2017.08.015
  15. Dekleva M, Celic V, Kostic N, Pencic B, Ivanovic AM, Caparevic Z. Left ventricular diastolic dysfunction is related to oxidative stress and exercise capacity in hypertensive patients with preserved systolic function. Cardiology 2007; 108: 62-70. https://doi.org/10.1159/000095883
  16. Lucas JS, Barbato A, Collins SA, et al. European Respiratory Society guidelines for the diagnosis of primary ciliary dyskinesia. Eur Respir J 2017; 49: 1601090. https://doi.org/10.1183/13993003.01090-2016
  17. Shoemark A, Frost E, Dixon M, et al. Accuracy of immunofluorescence in the diagnosis of primary ciliary dyskinesia. Am J Respir Crit Care Med 2017; 196: 94-101. https://doi.org/10.1164/rccm.201607-1351OC
  18. Rosenstein BJ, Cutting GR. The diagnosis of cystic fibrosis: a consensus statement. Cystic fibrosis foundation consensus panel. J Pediatr 1998; 132: 589-595. https://doi.org/10.1016/s0022-3476(98)70344-0
  19. Stanojevic S, Kaminsky DA, Miller MR, et al. ERS/ATS technical standard on interpretive strategies for routine lung function tests. Eur Respir J 2022; 60: 2101499. https://doi.org/10.1183/13993003.01499-2021
  20. Lee TW, Brownlee KG, Conway SP, Denton M, Littlewood JM. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cyst Fibros 2003; 2: 29-34. https://doi.org/10.1016/S1569-1993(02)00141-8
  21. Sylvia LG, Bernstein EE, Hubbard JL, Keating L, Anderson EJ. Practical guide to measuring physical activity. J Acad Nutr Diet 2014; 114: 199-208. https://doi.org/10.1016/j.jand.2013.09.018
  22. Bradley J, Howard J, Wallace E, Elborn S. Validity of a modified shuttle test in adult cystic fibrosis. Thorax 1999; 54: 437-439. https://doi.org/10.1136/thx.54.5.437
  23. Budziareck MB, Pureza Duarte RR, Barbosa-Silva MC. Reference values and determinants for handgrip strength in healthy subjects. Clin Nutr 2008; 27: 357-362. https://doi.org/10.1016/j.clnu.2008.03.008
  24. Schlüssel MM, dos Anjos LA, de Vasconcellos MT, Kac G. Reference values of handgrip dynamometry of healthy adults: a population-based study. Clin Nutr 2008; 27: 601-607. https://doi.org/10.1016/j.clnu.2008.04.004
  25. Livraghi A, Randell SH. Cystic fibrosis and other respiratory diseases of impaired mucus clearance. Toxicol Pathol 2007; 35: 116-129. https://doi.org/10.1080/01926230601060025
  26. Leite LR, Queiroz KCV, Coelho CC, Vergara AA, Donadio MVF, Aquino EDS. Functional performance in the modified shuttle test in children and adolescents with cystic fibrosis. Rev Paul Pediatr 2021; 39: e2019322. https://doi.org/10.1590/1984-0462/2021/39/2019322
  27. Sahlberg ME, Svantesson U, Thomas EM, Strandvik B. Muscular strength and function in patients with cystic fibrosis. Chest 2005; 127: 1587-1592. https://doi.org/10.1378/chest.127.5.1587
  28. Simsek S, Inal-Ince D, Cakmak A, et al. Reduced anaerobic and aerobic performance in children with primary ciliary dyskinesia. Eur J Pediatr 2018; 177: 765-773. https://doi.org/10.1007/s00431-018-3121-2
  29. Wells GD, Wilkes DL, Schneiderman JE, Thompson S, Coates AL, Ratjen F. Physiological correlates of pulmonary function in children with cystic fibrosis. Pediatr Pulmonol 2014; 49: 878-884. https://doi.org/10.1002/ppul.22928
  30. Cardoso J, Scalco J, Mucha F, Caputo F, Schivinski CS. Relationship between peripheral muscle strength, exercise capacity and body composition in children and adolescents with cystic fibrosis. Physiother Theory Pract 2022; 38: 3010-3017. https://doi.org/10.1080/09593985.2021.1973165
  31. Bousfiha A, Moundir A, Tangye SG, et al. The 2022 update of IUIS phenotypical classification for human inborn errors of immunity. J Clin Immunol 2022; 42: 1508-1520. https://doi.org/10.1007/s10875-022-01352-z
  32. Tangye SG, Al-Herz W, Bousfiha A, et al. Human inborn errors of immunity: 2022 Update on the classification from the international union of immunological societies expert committee. J Clin Immunol 2022; 42: 1473-1507. https://doi.org/10.1007/s10875-022-01289-3
  33. Yu JE. New primary immunodeficiencies 2023 update. Curr Opin Pediatr 2024; 36: 112-123. https://doi.org/10.1097/MOP.0000000000001315
  34. Struyf S, Proost P, Van Damme J. Regulation of the immune response by the interaction of chemokines and proteases. Adv Immunol 2003; 81: 1-44. https://doi.org/10.1016/s0065-2776(03)81001-5
  35. Shoemark A, Frost E, Harman K, et al. Nasal cavity inflammation in patients with primary ciliary dyskinesia (PCD) is associated with bacterial infection. Eur Respir J 2017; 50: OA4627. https://doi.org/10.1183/1393003.congress-2017.OA4627
  36. Marino LV, Harris A, Johnstone C, et al. Characterising the nutritional status of children with primary ciliary dyskinesia. Clin Nutr 2019; 38: 2127-2135. https://doi.org/10.1016/j.clnu.2018.08.034
  37. Kim HO, Kim HS, Youn JC, Shin EC, Park S. Serum cytokine profiles in healthy young and elderly population assessed using multiplexed bead-based immunoassays. J Transl Med 2011; 9: 113. https://doi.org/10.1186/1479-5876-9-113
  38. Kleiner G, Zanin V, Monasta L, et al. Pediatric patients with inflammatory bowel disease exhibit increased serum levels of proinflammatory cytokines and chemokines, but decreased circulating levels of macrophage inhibitory protein-1β, interleukin-2 and interleukin-17. Exp Ther Med 2015; 9: 2047-2052. https://doi.org/10.3892/etm.2015.2370
  39. Sznurkowska K, Kaźmierska K, Śledziński T, Zagierski M, Liberek A, Szlagatys-Sidorkiewicz A. Serum chemerin level, cytokine profile and nutritional status in children with cystic fibrosis. Acta Biochim Pol 2019; 66: 445-449. https://doi.org/10.18388/abp.2019_2858
  40. Moser C, Nussbaum E, Cooper DM. Circulating IL-1β, IGF-I, and fitness in cystic fibrosis. Pediatric Research 1999: 45; 353A. https://doi.org/10.1203/00006450-199904020-02098
  41. Zihlif N, Paraskakis E, Tripoli C, Lex C, Bush A. Markers of airway inflammation in primary ciliary dyskinesia studied using exhaled breath condensate. Pediatr Pulmonol 2006; 41: 509-514. https://doi.org/10.1002/ppul.20344
  42. Reula A, Escribano A, Castillo S, et al. Oxidative stress in ciliated nasal epithelial cells from patients with primary ciliary dyskinesia. Eur Respir J 2016: 48; PA1224. https://doi.org/10.1183/13993003.congress-2016.PA1224
  43. Olveira C, Padilla A, Dorado A, et al. Inflammation and oxidation biomarkers in patients with cystic fibrosis: the influence of azithromycin. Eurasian J Med 2017; 49: 118-123. https://doi.org/10.5152/eurasianjmed.2017.17010
  44. Benabdeslam H, Abidi H, Garcia I, Bellon G, Gilly R, Revol A. Lipid peroxidation and antioxidant defenses in cystic fibrosis patients. Clin Chem Lab Med 1999; 37: 511-516. https://doi.org/10.1515/CCLM.1999.082
  45. Galiniak S, Mołoń M, Rachel M. Links between disease severity, bacterial infections and oxidative stress in cystic fibrosis. Antioxidants (Basel) 2022; 11: 887. https://doi.org/10.3390/antiox11050887
  46. Feuillet-Fieux MN, Nguyen-Khoa T, Loriot MA, et al. Glutathione S-transferases related to P. aeruginosa lung infection in cystic fibrosis children: preliminary study. Clin Biochem 2009; 42: 57-63. https://doi.org/10.1016/j.clinbiochem.2008.09.116
  47. Ventura E, Durant R, Jaussent A, et al. Homocysteine and inflammation as main determinants of oxidative stress in the elderly. Free Radic Biol Med 2009; 46: 737-744. https://doi.org/10.1016/j.freeradbiomed.2008.11.002